Withdrawal of Heart Failure Treatment Patients With Non-ischemic Cardiomyopathy Who Have Been Super-responders to Cardiac Resynchronization Therapy.

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut d'Investigació Biomèdica de Bellvitge

About this trial

Multicenter, prospective, non-inferiority, randomized, single-blind (primary endpoint evaluators blinded, patients not blinded) clinical trial.

We aim to evaluate if the withdrawal of heart failure treatment is safe in patients with non-ischemic cardiomyopathy, negative genetic test, no evidence of late gadolinium enhancement on cardiac MRI, who have been super-responders to cardiac resynchronization therapy and remain free of heart failure events for at least 6 months after device implantation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of non-ischemic cardiomyopathy

LBBB already present at the time of first diagnosis of LV dysfunction

Negative genetic test

Cardiac MRI with no evidence of late gadolinium enhancement (LGE at RV insertion points is acceptable)

Disqualifiers

Family history of non-ischemic cardiomyopathy with LVEF <50% in at least one first-degree relative

Severe valvular heart disease

History of sustained ventricular arrhythmia or treated by ICD

Need to maintain beta-blocker therapy for other arrhythmias

Trial design

Design model

Parallel

Treatments tested in this trial

  • Withdrawal of Heart failure medications

    Drug

    Heart failure drugs will be withdrawn progressively over a maximum of 9 weeks, discontinuing drugs one by one following a predefined sequence

Treatment groups

64 Participants
are divided into 2 treatment groups
Group A: Control GroupNo intervention 0 interventions
Group B: Drugs withdrawal groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Recurrence of left ventricular dysfunction or heart failure symptoms at 6 months

Any of the following events: * Decrease in LVEF \>10% and final LVEF \<50% * Decrease in LVEF \>10% and increase in LV end-systolic volume \>15% * Appearance of heart failure symptoms accompanied by elevated NT-proBNP requiring initiation of oral, subcutaneous, or intravenous loop diuretic treatment.

Time frame
6 months

Secondary outcomes

1

Emergency room or day hospital visits for heart failure

Time frame
6 and 12 months
2

Hospitalizations due to heart failure

Time frame
6 and 12 months
3

Ventricular arrhythmias

Sustained ventricular tachycardia, sudden cardiac death, appropriate ICD therapy

Time frame
6 and 12 months
4

Supraventricular arrhythmias

Sustained supraventricular arrhythmia, including sustained atrial fibrillation, sustained atrial flutter and sustained atrial tachycardia

Time frame
6 and 12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Institut d'Investigació Biomèdica de Bellvitge

Lead sponsor

University Hospital Virgen de las Nieves

Collaborator

Hospital de Sant Pau

Collaborator

Hospital Vall d'Hebron

Collaborator

Hospital Universitario La Paz

Collaborator

Hospital Universitari de Bellvitge

Collaborator